X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SHASUN PHARMA Fact Sheet, SHASUN PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA Fact Sheet   (SHSCH)

Here is the latest financial fact sheet of SHASUN PHARMA. For more details, see the SHASUN PHARMA quarterly results and SHASUN PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

SHASUN PHARMA Price History

Price Rs 428.9
Mkt Cap Rs m 25,774
Vol '000 79.8
P/E X 123.9
P/CF X 28.8
EPS (TTM) Rs 3.5
% ch % 5.5
No. of shares m 60.10
% ch week % 11.9
% ch 1-mth % 7.4
% ch 12-mth % 102.2
52 week H/L Rs 432.1/211.6
(As on Nov 17, 2015 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SHASUN PHARMA Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
SHASUN PHARMA EQUITY SHARE DATA
High Rs541019218694 
Low Rs1249386046 
Sales per share (Unadj.) Rs158.4171.9193.5191.6214.2 
Earnings per share (Unadj.) Rs0.8-2.918.29.45.3 
Diluted earnings per shareRs0.6-2.416.78.85.0 
Cash flow per share (Unadj.) Rs8.64.825.618.715.8 
Dividends per share (Unadj.) Rs1.000.302.401.501.00 
Adj. dividends per shareRs0.800.242.201.410.94 
Dividend yield (eoy) %3.00.43.71.21.4 
Book value per share (Unadj.) Rs24.417.340.247.753.3 
Adj. book value per shareRs19.614.036.844.950.3 
Shares outstanding (eoy) m48.3148.5455.1256.6256.62 
Bonus/Rights/Conversions  -ESOPPIPI- 
Price / Sales ratio x0.20.40.30.60.3 
Avg P/E ratio x42.4-25.83.613.113.1 
P/CF ratio (eoy) x3.815.52.56.64.4 
Price / Book Value ratio x1.44.31.62.61.3 
Dividend payout %128.5-10.313.216.018.7 
Avg Mkt Cap Rs m1,5943,6413,5836,9643,958 
No. of employees `0001.5NA1.5NANA 
Total wages/salary Rs m1,4031,4321,5941,8662,164 
Avg. sales/employee Rs Th5,278.9NM7,109.3NMNM 
Avg. wages/employee Rs Th967.7NM1,062.7NMNM 
Avg. net profit/employee Rs Th25.9NM670.5NMNM 
SHASUN PHARMA INCOME DATA
Net Sales Rs m7,6548,34510,66410,84812,127 
Other income Rs m221220130183229 
Total revenues Rs m7,8758,56410,79411,03012,356 
Gross profit Rs m2927151,2301,1021,009 
Depreciation Rs m379376406527594 
Interest Rs m301323437255415 
Profit before tax Rs m-167236517504230 
Minority Interest Rs m00000 
Prior Period Items Rs m0-408000 
Extraordinary Inc (Exp) Rs m187028000 
Tax Rs m-18-30-209-26-73 
Profit after tax Rs m38-1411,006530302 
Gross profit margin %3.88.611.510.28.3 
Effective tax rate %10.5-12.8-40.5-5.2-31.7 
Net profit margin %0.5-1.79.44.92.5 
SHASUN PHARMA BALANCE SHEET DATA
Current assets Rs m3,8863,7254,7925,3126,884 
Current liabilities Rs m2,0764,7465,5456,4918,456 
Net working cap to sales %23.6-12.2-7.1-10.9-13.0 
Current ratio x1.90.80.90.80.8 
Inventory Days Days4556475762 
Debtors Days Days92697989108 
Net fixed assets Rs m2,7462,6043,3084,4564,970 
Share capital Rs m9797110113113 
"Free" reserves Rs m9077392,0822,6052,875 
Net worth Rs m1,1788392,2132,7003,020 
Long term debt Rs m3,2646727791,1831,817 
Total assets Rs m6,6356,5458,60510,44513,347 
Interest coverage x0.41.72.23.01.6 
Debt to equity ratio x2.80.80.40.40.6 
Sales to assets ratio x1.21.31.21.00.9 
Return on assets %5.12.816.87.55.4 
Return on equity %3.2-16.845.419.610.0 
Return on capital %7.210.041.219.513.3 
Exports to sales %40.646.846.747.046.4 
Imports to sales %10.813.714.413.714.2 
Exports (fob) Rs m3,1073,9024,9825,1015,622 
Imports (cif) Rs m8261,1471,5351,4841,728 
Fx inflow Rs m3,2834,0115,0835,2585,843 
Fx outflow Rs m8281,3441,7911,7072,173 
Net fx Rs m2,4542,6673,2923,5523,669 
SHASUN PHARMA CASH FLOW
From Operations Rs m 370 590 508 349 398 
From Investments Rs m 96 -321 -773 -1,611 -1,635 
From Financial Activity Rs m -398 -279 316 1,172 1,309 
Net Cashflow Rs m 68 -10 52 -90 71 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 39.2%
Foreign collaborators 0.0%
Indian inst/Mut Fund 3.6%
FIIs 17.6%
ADR/GDR 0.0%
Free float 39.6%
Shareholders 20,750
Pledged promoter(s) holding 12.3%
 

Company Information

REGD OFF Batra Centre, 3rd & 4th Floor, 28, Sardar Patel Road, Guindy, Chennai - 600 032
E-MAIL muralikrishna@shasun.com WEB www.shasun.com
TELEPHONE (044) 4344 6700 FAX (044) 2235 0278
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Integrated Enterprises, Kences Towers, Ramakrishna St., Chennai-17
AUDITOR B. S. R & Co.
CHM: R. Kannan COMP SEC: S. Murali Krishna YEAR OF INC: 1976 BSE CODE: 524552 FV (Rs): 2 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   INDOCO REMEDIES  FRESENIUS KABI ONCO.  AUROBINDO PHARMA  FULFORD INDIA  BIOCON LTD  

Compare SHASUN PHARMA With:   INDOCO REMEDIES  FRESENIUS KABI ONCO.  AUROBINDO PHARMA  FULFORD INDIA  BIOCON LTD  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak End to the Week; Auto & PSU Stocks Fall(Closing)

Profit booking continued in the afternoon session in the Indian share markets amid weak European cues. At the closing bell, the BSE Sensex stood lower by 153 points.

Views on news

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Should You Trade In Mutual Funds As You Do In Stocks?(Outside View)

Jun 10, 2017

Trading is not synonymous with mutual funds, PersonalFN explains.

Which Way Will Inflation Go?(Chart Of The Day)

Jun 10, 2017

RBI and government at loggerheads over interest rates.

More

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SHASUN PHARMA

SHASUN PHARMA - NATCO PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS